Dynacure

OverviewSuggest Edit

Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. The Company program is focused on Centronuclear Myopathies (CNM), a debilitating disease affecting children and young adults. It is based on the modulation of the expression of the Dynamin 2 protein, through the use of an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals.
TypePrivate
Founded2016
HQIllkirch-Graffenstaden, FR
Websitedynacure.com

Latest Updates

Employees (est.) (Sept 2021)31
Cybersecurity ratingBMore

Key People/Management at Dynacure

Stéphane van Rooijen

Stéphane van Rooijen

CEO, Board Member
Benoit Barteau

Benoit Barteau

Board Member
Frédéric Legros

Frédéric Legros

COO
Frédéric Chereau

Frédéric Chereau

Board Member
Chris Freitag

Chris Freitag

CMO
Rémi Droller

Rémi Droller

Board Member
Show more

Dynacure Office Locations

Dynacure has an office in Illkirch-Graffenstaden
Illkirch-Graffenstaden, FR (HQ)
Bioparc 3, 850 boulevard Sébastien Brant
Show all (1)

Dynacure Financials and Metrics

Summary Metrics

Founding Date

2016

Dynacure total Funding

$113.5 m

Dynacure latest funding size

$54.82 m

Time since last funding

a year ago

Dynacure investors

Dynacure's latest funding round in April 2020 was reported to be $54.8 m. In total, Dynacure has raised $113.5 m
Show all financial metrics

Dynacure Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Dynacure Online and Social Media Presence

Embed Graph

Dynacure News and Updates

Dynacure Announces FDA Acceptance of Investigational New Drug Application for DYN101 for Myotubular and Centronuclear Myopathies

STRASBOURG, France and PHILADELPHIA, June 9, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the US Food...

Dynacure Recognizes Rare Disease Day 2021

STRASBOURG, France and PHILADELPHIA, Feb. 26, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, today announced its recognition...

Dynacure Announces Issuance of U.S. Patent for DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)

STRASBOURG, France and PHILADELPHIA, Jan. 26, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the U.S....

Dynacure Announces Appointment of Jean M. Franchi to its Board of Directors

STRASBOURG, France and PHILADELPHIA, Jan. 21, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today the appointment...

Dynacure Announces New Program, DYN201, for Hereditary Spastic Paraplegia (HSP), a Rare Neurodegenerative Disease

STRASBOURG, France and PHILADELPHIA, Oct. 13, 2020 /PRNewswire/ -- Dynacure, a clinical-stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that they have entered into a license agreement with the Paris Brain Institute...

Dynacure Announces €50M ($55M) Series C Financing

STRASBOURG, France and PHILADELPHIA, April 2, 2020 /PRNewswire/ -- Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today the close of a €50 million Series C financing led by Perceptive Advisors. New...
Show more

Dynacure Blogs

Dynacure to Present Preclinical Data on Disease Progression Modelling and ASO-Mediated Dynamin 2 Knockdown at World Muscle Society (WMS) Meeting

Company is advancing treatments designed to reduce the expression of disease-causing proteins in Myotubular and Centronuclear Myopathies and other neuromuscular disorders with high unmet needSTRASBOURG, France and PHILADELPHIA, Sept. 16, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focuse…

Dynacure Frequently Asked Questions

  • When was Dynacure founded?

    Dynacure was founded in 2016.

  • Who are Dynacure key executives?

    Dynacure's key executives are Stéphane van Rooijen, Benoit Barteau and Frédéric Legros.

  • How many employees does Dynacure have?

    Dynacure has 31 employees.

  • Who are Dynacure competitors?

    Competitors of Dynacure include Alembic Pharmaceuticals, EMS Pharma and Cipla.

  • Where is Dynacure headquarters?

    Dynacure headquarters is located at Bioparc 3, 850 boulevard Sébastien Brant, Illkirch-Graffenstaden.

  • Where are Dynacure offices?

    Dynacure has an office in Illkirch-Graffenstaden.

  • How many offices does Dynacure have?

    Dynacure has 1 office.